UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

European journal of drug metabolism and pharmacokinetics, 2019-12, Vol.44 (6), p.747-759

2019

Volltextzugriff (PDF)

Marketing in schools, commercialization and sustainability: policy disjunctures surrounding the commercialization of childhood and education for sustainable lifestyles in England

Educational review (Birmingham), 2016-01, Vol.68 (1), p.56-70

Wilkinson, Gary

2016

Volltextzugriff (PDF)

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

Journal of medicinal chemistry, 2018-11, Vol.61 (22), p.9889-9907

2018

Volltextzugriff (PDF)

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity

European journal of cancer (1990), 2019-03, Vol.109, p.103-110

2019

Volltextzugriff (PDF)

Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment

Clinical pharmacokinetics, 2022-04, Vol.61 (4), p.565-575

2022

Volltextzugriff (PDF)

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

Cancer discovery, 2021-01, Vol.11 (1), p.80-91

2021

Volltextzugriff (PDF)

First-in-human dose escalation study of the first-in-class PDE3A-SLFN12 complex inducer BAY 2666605 in patients with advanced solid tumors co-expressing SLFN12 and PDE3A

Clinical cancer research, 2024-10

2024

Volltextzugriff (PDF)

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Leukemia, 2020-11, Vol.34 (11), p.2903-2913

2020

Volltextzugriff (PDF)

Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.297-297

2019

Volltextzugriff (PDF)

Workforce remodelling and formal knowledge: the erosion of teachers' professional jurisdiction in English schools

School leadership & management, 2005-11, Vol.25 (5), p.421-439

Wilkinson, Gary

2005

Volltextzugriff (PDF)

Abstract 311: Optimization of treatment schedule for the combination therapy of ATR inhibitor elimusertib and PARP inhibitor niraparib in preclinical tumor models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.311-311

2023

Volltextzugriff (PDF)

Civic Professionalism: Teacher Education and Professional Ideals and Values in a Commercialised Education World

Journal of education for teaching : JET, 2007-08, Vol.33 (3), p.379-395

Wilkinson, Gary

2007

Volltextzugriff (PDF)

Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT015-CT015

2019

Volltextzugriff (PDF)

Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy

Cancers, 2019-12, Vol.11 (12), p.1987

2019

Volltextzugriff (PDF)

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3007-3007

2019

Volltextzugriff (PDF)

Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent

Investigational new drugs, 2004-08, Vol.22 (3), p.231-240

2004

Volltextzugriff (PDF)

Pedagogy of the possessed: the privatization of civic education and values under New Labour

Educational review (Birmingham), 2007-08, Vol.59 (3), p.267-284

Wilkinson, Gary

2007

Volltextzugriff (PDF)

McSchools for McWorld? Mediating global pressures with a McDonaldizing education policy response

Cambridge journal of education, 2006-03, Vol.36 (1), p.81-98

Wilkinson, Gary

2006

Volltextzugriff (PDF)

Child-Pugh versus NCI-ODWG categorization for hepatic impairment studies - observations from a renal and hepatic impairment study with darolutamide, a novel investigational androgen receptor antagonist

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018, Vol.WCP2018, p.OR22-2

2018

Volltextzugriff (PDF)

Civic professionalism: teacher education and professional ideals and values in a commercialised education world1

Journal of education for teaching : JET, 2007-08, Vol.33 (3), p.379-395

Wilkinson, Gary

2007

Volltextzugriff (PDF)

Commercial Breaks: An Overview of Corporate Opportunities for Commercializing Education in US and English Schools

London review of education, 2006-11, Vol.4 (3), p.253

Wilkinson, Gary

2006

Volltextzugriff (PDF)

Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT006-CT006

2022

Volltextzugriff (PDF)

Translational modelling of preclinical cardiovascular findings to patients

Journal of pharmacological and toxicological methods, 2014-11, Vol.70 (3), p.326-327

2014

Volltextzugriff (PDF)

Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2348-2348

2013

Volltextzugriff (PDF)

Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40

MedChemComm, 2015-01, Vol.6 (6), p.1024-1029

2015

Volltextzugriff (PDF)

1 – 25 von 472

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(409)
Mit Volltextzugriff
(400)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(471)
Portugiesisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Marketing in schools, commercialization and sustainability: policy disjunctures surrounding the commercialization of childhood and education for sustainable lifestyles in England

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity

Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

First-in-human dose escalation study of the first-in-class PDE3A-SLFN12 complex inducer BAY 2666605 in patients with advanced solid tumors co-expressing SLFN12 and PDE3A

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies

Workforce remodelling and formal knowledge: the erosion of teachers' professional jurisdiction in English schools

Abstract 311: Optimization of treatment schedule for the combination therapy of ATR inhibitor elimusertib and PARP inhibitor niraparib in preclinical tumor models

Civic Professionalism: Teacher Education and Professional Ideals and Values in a Commercialised Education World

Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer

Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors

Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent

Pedagogy of the possessed: the privatization of civic education and values under New Labour

McSchools for McWorld? Mediating global pressures with a McDonaldizing education policy response

Child-Pugh versus NCI-ODWG categorization for hepatic impairment studies - observations from a renal and hepatic impairment study with darolutamide, a novel investigational androgen receptor antagonist

Civic professionalism: teacher education and professional ideals and values in a commercialised education world1

Commercial Breaks: An Overview of Corporate Opportunities for Commercializing Education in US and English Schools

Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects

Translational modelling of preclinical cardiovascular findings to patients

Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients

Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40

Suchergebnisse filtern